According to the adenosine hypothesis of schizophrenia, the classically associated hyperdopaminergic state may be secondary to a loss of function of the adenosinergic system. Such a hypoadenosinergic state might either be due to a reduction of the extracellular levels of adenosine or alterations in the density of adenosine A receptors (ARs) or their degree of functional heteromerization with dopamine D receptors (DR). In the present study, we provide preclinical and clinical evidences for this latter mechanism. Two animal models for the study of schizophrenia endophenotypes, namely the phencyclidine (PCP) mouse model and the AR knockout mice, were used to establish correlations between behavioural and molecular studies. In addition, a new AlphaLISA-based method was implemented to detect native AR-DR heteromers in mouse and human brain. First, we observed a reduction of prepulse inhibition in AR knockout mice, similar to that observed in the PCP animal model of sensory gating impairment of schizophrenia, as well as a significant upregulation of striatal DR without changes in AR expression in PCP-treated animals. In addition, PCP-treated animals showed a significant reduction of striatal AR-DR heteromers, as demonstrated by the AlphaLISA-based method. A significant and pronounced reduction of AR-DR heteromers was next demonstrated in postmortem caudate nucleus from schizophrenic subjects, even though both DR and AR were upregulated. Finally, in PCP-treated animals, sub-chronic administration of haloperidol or clozapine counteracted the reduction of striatal AR-DR heteromers. The degree of AR-DR heteromer formation in schizophrenia might constitute a hallmark of the illness, which indeed should be further studied to establish possible correlations with chronic antipsychotic treatments.
About The Expert
Marta Valle-León
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
Luis F Callado
- Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Leioa, Spain.
- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Ester Aso
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
María M Cajiao-Manrique
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
- Bordeaux International Neuroscience Master, University of Bordeaux, Bordeaux, France.
Kristoffer Sahlholm
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.
Marc López-Cano
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
Concepció Soler
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
- Immunology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
Xavier Altafaj
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
Masahiko Watanabe
- Department of Anatomy, Hokkaido University School of Medicine, Sapporo, 060-0818, Japan.
Sergi Ferré
- Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. sferre@intra.nida.nih.gov.
Víctor Fernández-Dueñas
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
José M Menchón
- Department of Psychiatry, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain.
- Psychiatry and Mental Health Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
- Department of Clinical Sciences, School of Medicine, University of Barcelona, UB, L’Hospitalet de Llobregat, Barcelona, Spain.
- Ciber Salud Mental (CIBERSAM), Instituto Salud Carlos III, Madrid, Spain.
Francisco Ciruela
- Pharmacology Unit, Faculty of Medicine and Health Sciences, Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain. fciruela@ub.edu.
- Neuropharmacology and Pain Group, Neuroscience Program, Institut d’Investigació Biomèdica de Bellvitgee, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. fciruela@ub.edu.
References
PubMed